Cover Image
市場調查報告書

巨細胞病毒(HHV-5)感染疾病:開發中產品分析

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229755
出版日期 內容資訊 英文 177 Pages
訂單完成後即時交付
價格
Back to Top
巨細胞病毒(HHV-5)感染疾病:開發中產品分析 Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 177 Pages
簡介

巨細胞病毒(CMV)是皰疹病毒科的一種,是由病毒所引起的傳染性疾病。CMV會藉由唾液、尿來傳染。常見的症狀有發燒、肺炎、體重減輕、聽障、神經病變、發育障礙等。容易罹患的危險因子除了直接接觸受感染的表面及生物之外,還有免疫力不足、先天性因素等。可以血液檢查及尿液檢查診斷出。可以服藥(抗病毒藥等)來降低症狀、或改善生活習慣等。

本報告提供巨細胞病毒(HHV-5)感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

巨細胞病毒(HHV-5)感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Adicet Bio, Inc.
  • AIMM Therapeutics B.V.
  • Altor BioScience Corporation
  • Astellas Pharma Inc.
  • Atara Biotherapeutics, Inc.
  • Bionor Pharma ASA
  • Biotest AG
  • Cell Medica Limited
  • Chimerix, Inc.
  • China Biologic Products, Inc.
  • CyTuVax B.V.
  • Fate Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Hookipa Biotech AG.
  • Humabs BioMed SA.
  • Kadmon Corporation, LLC
  • Laboratoires Thea S.A.
  • Merck & Co., Inc.
  • Microbiotix, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Phoenix Biotechnology, Inc.
  • Savoy Pharmaceuticals, Inc.
  • Sigma-Tau S.p.A.
  • Trellis Bioscience, Inc.
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc.
  • Vical Incorporated

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8694IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 7
  • Introduction 8
  • Global Markets Direct Report Coverage 8
  • Cytomegalovirus (HHV-5) Infections Overview 9
  • Therapeutics Development 10
  • Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10
  • Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11
  • Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12
  • Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 14
  • Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16
  • Late Stage Products 16
  • Clinical Stage Products 17
  • Early Stage Products 18
  • Unknown Stage Products 19
  • Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20
  • Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23
  • Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 25
  • Adicet Bio, Inc. 25
  • AIMM Therapeutics BV 26
  • Astellas Pharma Inc 27
  • Atara Biotherapeutics Inc 28
  • AvidBiotics Corp 29
  • Biotest AG 30
  • Chimerix Inc 31
  • China Biologic Products Inc 32
  • CyTuVax BV 33
  • Fate Therapeutics Inc 34
  • GlaxoSmithKline Plc 35
  • Hookipa Biotech AG 36
  • Kadmon Corp LLC 37
  • Laboratoires Thea SA 38
  • Merck & Co Inc 39
  • Microbiotix Inc 40
  • Mymetics Corp 41
  • Novartis AG 42
  • Pfizer Inc 43
  • Phoenix Biotechnology Inc 44
  • Savoy Pharmaceuticals, Inc. 45
  • Sigma-Tau SpA 46
  • Themis Bioscience GmbH 47
  • Trellis Bioscience Inc 48
  • Vakzine Projekt Management GmbH 49
  • VBI Vaccines Inc 50
  • Vical Inc 51
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52
  • Assessment by Monotherapy Products 52
  • Assessment by Combination Products 53
  • Assessment by Target 54
  • Assessment by Mechanism of Action 56
  • Assessment by Route of Administration 58
  • Assessment by Molecule Type 60
  • Drug Profiles 62
  • AIC-387 - Drug Profile 62
  • AIC-476 - Drug Profile 63
  • AIC-813 - Drug Profile 64
  • AL-18 - Drug Profile 65
  • Antibody for Human Cytomegalovirus Infection - Drug Profile 66
  • ASP-0113 - Drug Profile 67
  • brincidofovir - Drug Profile 70
  • BT-084 - Drug Profile 84
  • Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile 85
  • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 86
  • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 87
  • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 88
  • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 89
  • Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile 90
  • Cellular Immunotherapy for Infectious Disease - Drug Profile 91
  • Cellular Immunotherapy for Infectious Diseases - Drug Profile 92
  • Cellular Immunotherapy for Viral Infections - Drug Profile 93
  • Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 94
  • Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 95
  • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 96
  • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 98
  • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 99
  • CMX-669 - Drug Profile 100
  • CSJ-148 - Drug Profile 101
  • CyMVectin - Drug Profile 102
  • cytomegalovirus (virus like particle) vaccine - Drug Profile 104
  • Cytomegalovirus (virus like particle) vaccine - Drug Profile 105
  • Cytomegalovirus vaccine - Drug Profile 106
  • Cytomegalovirus vaccine - Drug Profile 107
  • Cytomegalovirus vaccine - Drug Profile 108
  • filociclovir - Drug Profile 109
  • ganciclovir - Drug Profile 111
  • Gene Therapy for Cytomegalovirus Infections - Drug Profile 112
  • HB-101 - Drug Profile 113
  • letermovir - Drug Profile 114
  • maribavir - Drug Profile 117
  • MBX-2168 - Drug Profile 120
  • Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 121
  • Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 122
  • Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile 123
  • Pentamer - Drug Profile 124
  • Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 125
  • PepVax - Drug Profile 126
  • ProTmune - Drug Profile 128
  • PTX-3 - Drug Profile 130
  • RBT-301 - Drug Profile 131
  • Recombinant Peptide for Infectious Diseases - Drug Profile 132
  • Recombinant Protein for CMV - Drug Profile 133
  • RKP-00156 - Drug Profile 134
  • Small Molecule for Cytomegalovirus - Drug Profile 135
  • Small Molecules for CMV Infections - Drug Profile 136
  • Small Molecules for CMV infections and Cancer - Drug Profile 137
  • Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 138
  • Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 139
  • Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 140
  • Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 141
  • Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 142
  • Triplex - Drug Profile 143
  • TRL-345 - Drug Profile 145
  • V-160 - Drug Profile 146
  • VBI-1501A - Drug Profile 147
  • Viralym-C - Drug Profile 149
  • Viroprev - Drug Profile 150
  • VPM-2001 - Drug Profile 151
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects 152
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products 157
  • Cytomegalovirus (HHV-5) Infections - Product Development Milestones 158
  • Featured News & Press Releases 158
  • Appendix 172
  • Methodology 172
  • Coverage 172
  • Secondary Research 172
  • Primary Research 172
  • Expert Panel Validation 172
  • Contact Us 172
  • Disclaimer 173

List of Tables

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14
  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016 15
  • Number of Products under Development by Companies, H2 2016 16
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 17
  • Number of Products under Investigation by Universities/Institutes, H2 2016 19
  • Comparative Analysis by Late Stage Development, H2 2016 20
  • Comparative Analysis by Clinical Stage Development, H2 2016 21
  • Comparative Analysis by Early Stage Development, H2 2016 22
  • Comparative Analysis by Unknown Stage Development, H2 2016 23
  • Products under Development by Companies, H2 2016 24
  • Products under Development by Companies, H2 2016 (Contd..1) 25
  • Products under Development by Companies, H2 2016 (Contd..2) 26
  • Products under Investigation by Universities/Institutes, H2 2016 27
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 28
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H2 2016 29
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H2 2016 30
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H2 2016 31
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2016 32
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H2 2016 33
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2016 34
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H2 2016 35
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H2 2016 36
  • Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H2 2016 37
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2016 38
  • Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 39
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2016 40
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H2 2016 41
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H2 2016 42
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2016 43
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H2 2016 44
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Mymetics Corp, H2 2016 45
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2016 46
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H2 2016 47
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2016 48
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 49
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H2 2016 50
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H2 2016 51
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H2 2016 52
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2016 53
  • Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H2 2016 54
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H2 2016 55
  • Assessment by Monotherapy Products, H2 2016 56
  • Assessment by Combination Products, H2 2016 57
  • Number of Products by Stage and Target, H2 2016 59
  • Number of Products by Stage and Mechanism of Action, H2 2016 61
  • Number of Products by Stage and Route of Administration, H2 2016 63
  • Number of Products by Stage and Molecule Type, H2 2016 65
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2016 156
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H2 2016 157
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H2 2016 158
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H2 2016 159
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H2 2016 160
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2016 161

List of Figures

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14
  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016 15
  • Number of Products under Development by Companies, H2 2016 16
  • Number of Products under Investigation by Universities/Institutes, H2 2016 18
  • Comparative Analysis by Late Stage Development, H2 2016 20
  • Comparative Analysis by Clinical Stage Development, H2 2016 21
  • Comparative Analysis by Early Stage Products, H2 2016 22
  • Assessment by Monotherapy Products, H2 2016 56
  • Number of Products by Top 10 Targets, H2 2016 58
  • Number of Products by Stage and Top 10 Targets, H2 2016 58
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 60
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 60
  • Number of Products by Routes of Administration, H2 2016 62
  • Number of Products by Stage and Routes of Administration, H2 2016 62
  • Number of Products by Top 10 Molecule Types, H2 2016 64
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 64
Back to Top